Vaxcyte Corporate Presentation
Potential for Global Pneumococcal Market to Grow Beyond the $7B Today
о
The Oct. 2021 ACIP Vote Reinforced Need for PCVs with Broader Spectrum of Coverage and for Use in Expanded Adult Population
➤ ACIP supported use of
either Pfizer's PCV20 or
Merck's PCV15 plus
Pneumovax23 in adults ≥65
years of age
By preserving PPV23, ACIP
decision reinforces the need
for a 24-valent PCV
➤ Age-based recommendation remains at
age 65, per ACIP
This is the first time ACIP has
recommended a PCV for risk groups
ages 19 to 64
Significantly expands adult
population and increases
overall PCV market
➤ Strong desire expressed by several ACIP
committee members to move adult
vaccination to 50 years of age
CDC committed to gathering more data
and revisiting at a future meeting
Provides important
opportunity to address
unmet needs in adultsView entire presentation